Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Journal Articles

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood (2023) 142 (Supplement 1): 3474.

https://doi.org/10.1182/blood-2023-173162

Published: 2023

Journal Articles

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Mika Kontro, Anthony Selwyn Stein, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Maija Hollmén, Marie-Louise Fjaellskog, Inka Pawlitzky, Amer M. Zeidan, Naval Daver

Blood (2023) 142 (Supplement 1): 2915.

https://doi.org/10.1182/blood-2023-174912

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Naval Daver, Anthony Selwyn Stein, Dale Bixby, Wanxing Chai-Ho, Joshua F. Zeidner, Keri Maher, Don A. Stevens, Maximilian Stahl, Karen Yee, Emily K Curran, Sawa Ito, Andrew Sochacki, David A Sallman, Robert Hernandez, Simon Metenou, Bo Ma, Kazunobu Kato, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2023-173991

Published: 2023

Journal Articles

A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia

Anthony Selwyn Stein, MD, Jeffrey Y. C. Wong, MD, Joycelynne Palmer, PhD, Margaret O'Donnell, MD, David S. Snyder, MD, Ni-Chun Tsai, Biostatition, Pablo Miguel Parker, MD, Ricardo Spielberger, MD, Len Farol, MD, Guido Marcucci, MD, Eric Radany, MD, Tim Schultheiss, MD, An Liu, MD, Ibrahim Aldoss, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 735.

https://doi.org/10.1182/blood.V126.23.735.735

Published: 2015

Journal Articles

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Anthony Selwyn Stein, MD, Max S. Topp, MD, Hagop M Kantarjian, MD, Nicola Goekbuget, MD, Ralf C Bargou, MD, Mark R Litzow, MD, Alessandro Rambaldi, MD, Josep Ribera, MD PhD, Alicia Zhang, PhD, Zachary Zimmerman, MD PhD, Stephen J. Forman, MD

Blood (2015) 126 (23): 861.

https://doi.org/10.1182/blood.V126.23.861.861

Published: 2015

Journal Articles

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Giovanni Martinelli, MD, Hervé Dombret, Patrice Chevallier, MD PhD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Max S. Topp, MD, Adele K. Fielding, MB BS, PhD, Lulu Ren Sterling, PhD, Jonathan Benjamin, MD, Anthony Selwyn Stein, MD

Blood (2015) 126 (23): 679.

https://doi.org/10.1182/blood.V126.23.679.679

Published: 2015

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Matched Cohort Analysis of Allogeneic Hematopoietic Cell Transplantation (HCT) with Total Marrow Irradiation/Fludarabine/Melphalan (TFM) Versus Fludarabine/Melphalan (FM) Conditioning for Acute Leukemia

Joseph Rosenthal, MD, Jefrrey Wong, MD, Anthony Selwyn Stein, MD, Tracy Stiller, Joycelynne Palmer, PHD, Stephen J. Forman, MD

Blood (2012) 120 (21): 222.

https://doi.org/10.1182/blood.V120.21.222.222

Published: 2012

Journal Articles

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Anthony Selwyn Stein, MD, Jeffrey Wong, MD, Joycelynne Palmer, PhD, Margaret O'Donnell, MD, David S. Snyder, MD, Ni-Chun Tsai, MS MPH, Pablo Parker, MD, Len Farol, MD, Ricardo Spielberger, MD, Firoozeh Sahebi, MD, Neil Kogut, MD, Joyce Murata-Collins, PhD, David Senitzer, PhD, Stephen J. Forman, MD

Blood (2012) 120 (21): 218.

https://doi.org/10.1182/blood.V120.21.218.218

Published: 2012

Journal Articles

Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades

Saro H. Armenian, DO, MPH, Can-Lan Sun, Ph.D, Tabitha Vase, George Mills, III, Liezl Atencio, Liton Francisco, Jocelynne Palmer, PhD, Ari VanderWalde, MD, MPH, F. Lennie Wong, PhD, Joseph Rosenthal, MD, Neil Martin Kogut, MD, Leslie Popplewell, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Margret O'Donnell, MD, Stephen J. Forman, MD, Smita Bhatia, MD, MPH

Blood (2012) 120 (21): 606.

https://doi.org/10.1182/blood.V120.21.606.606

Published: 2012

Journal Articles

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Pamela S. Becker, MD, PhD, Bruno C. Medeiros, MD, Anthony Selwyn Stein, M.D., Frederick R. Appelbaum, MD, Bart L Scott, MD, MS, Colleen Delaney, MD, MSc, Megan Othus, PhD, Paul C. Hendrie, MD, PhD, Kelda M. Gardner, PA-C, Stephen Petersdorf, MD, John M. Pagel, MD, PhD, Roland B. Walter, MD, PhD, Cynthia Parks, Elihu H. Estey, MD

Blood (2012) 120 (21): 3594.

https://doi.org/10.1182/blood.V120.21.3594.3594

Published: 2012

Journal Articles

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Ari M. Vander Walde, M.D., M.P.H., Can-Lan Sun, Ph.D., Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Neal Kogut, M.D., Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 933.

https://doi.org/10.1182/blood.V116.21.933.933

Published: 2010

Journal Articles

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Lester A. Laddaran, B.A., Can-Lan Sun, Ph.D., Ari M. VanderWalde, MD, MPH, Liton Francisco, B.S., Saro Armenian, D.O., M.P.H., Jennifer Berano Teh, M.D., F. Lennie Wong, Ph.D., Chatchada Karanes, MD, Neil Martin Kogut, MD, Amrita Krishnan, M.D., Auayporn Nademanee, M.D., Margaret O'Donnell, M.D., F.R.C.P.C., Pablo Parker, M.D., Leslie Popplewell, M.D., Anthony Selwyn Stein, M.D., Stephen J. Forman, M.D., Smita Bhatia

Blood (2010) 116 (21): 902.

https://doi.org/10.1182/blood.V116.21.902.902

Published: 2010

Journal Articles

Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.

Neil Martin Kogut, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Joyce Collins, PhD, Margaret O'Donnell, M.D., F.R.C.P.C., Anthony Selwyn Stein, M.D., Ricardo Spielberger, MD, Stephen Forman, MD

Blood (2010) 116 (21): 3467.

https://doi.org/10.1182/blood.V116.21.3467.3467

Published: 2010

Journal Articles

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Mark Kirschbaum, MD, Anthony Selwyn Stein, M.D., Paul Frankel, Leslie Popplewell, M.D., Robert w Chen, Maria L Delioukina, MD, Ryotaro Nakamura, MD, David S. Snyder, MD, Cynthia Slape, Christopher Ruel, Joel Conrad, Auayporn Nademanee, M.D., Stephen Forman, MD

Blood (2010) 116 (21): 528.

https://doi.org/10.1182/blood.V116.21.528.528

Published: 2010

Journal Articles

Improved Outcomes Using Tacrolimus/Sirolimus for graft Versus Host Disease prophylaxis with a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Myelofibrosis

David S. Snyder, MD, Joycelynne Palmer, Karl Gaal, Anthony Selwyn Stein, Vinod Pullarkat, Nyana Vora, Ryotaro Nakamura, Firoozeh Sahebi, Stephen J Forman

Blood (2008) 112 (11): 4410.

https://doi.org/10.1182/blood.V112.11.4410.4410

Published: 2008

Journal Articles

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Mark H. Kirschbaum, MD, Anthony Selwyn Stein, MD, Joseph Tuscano, MD, Jasmine M. Zain, MD, Leslie Popplewell, MD, Margaret R. O’Donnell, MD, Chatchada Karanes, MD, John Wright, MD, Bernadette Pulone, RN, Amalia Rincon, Paul Frankel, PhD, Stephen J. Forman, MD, Edward Newman, PhD

Blood (2007) 110 (11): 891.

https://doi.org/10.1182/blood.V110.11.891.891

Published: 2007

NARROW

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Encouraging Efficacy Observed in Bexmab Study: A Phase 1/2 Study to Assess Safety and Efficacy of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia

Treatment with Anti-CD19 BiTE ® Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Matched Cohort Analysis of Allogeneic Hematopoietic Cell Transplantation (HCT) with Total Marrow Irradiation/Fludarabine/Melphalan (TFM) Versus Fludarabine/Melphalan (FM) Conditioning for Acute Leukemia

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades

Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period

Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era

Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.

Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation

Improved Outcomes Using Tacrolimus/Sirolimus for graft Versus Host Disease prophylaxis with a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Myelofibrosis

A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week-On Week-Off Dose Schedule in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only